



QuikFlo provides update

Calgary, Alberta, June 7, 2016 – QuikFlo Health Inc. ("QuikFlo" or the "Company") (TSXV:QF)(FRANKFURT:1QF) announced that it has, subject to regulatory approval, appointed David Lane of Vancouver, BC as a director and interim CEO. Mr. Lane has significant experience as a director and officer of various public companies across various industry sectors. Michael Hill and Vinny Jindal have resigned as directors and president, and Dr. Ting Lee has resigned as CTO. The Company wishes to thank all for their contribution to the Company.

The Company also wishes to provide further information in respect to its investor relations engagement of Richard Olson and Phil Beaudoin of Toronto to provide investor relations services. With over 50 years of combined hands-on financial industry experience, both Richard and Phil continue to bring a truly unique IR proposition to their clients. Their involvement with many early stage companies have given them the perspective to provide strategic guidance to their clients to help manage through the early growth years. Each will be paid \$3,750 per month and receive 125,000 options, subject to regulatory approval. After July 31, 2016, this contract is on a month to month basis.

About QuikFlo

QuikFlo is a medical software company developing innovative solutions for the analysis of medical images. Its primary focus is on improving outcomes for stroke patients, where existing time delays are solvable through more efficient triage based on rapid, accurate analysis of medical images.

Further Information

For further information relating to the Company or this release please visit www.sedar.com, www.quikflohealth.com, or contact Investor Relations for the Company at 416.488.7572.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary and Forward-Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. Forward-looking statements are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although management of the Company believes that the expectations and assumptions on which such forward looking statements and information are based are currently reasonable, actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the suitability of the key members of ongoing management and the board of directors, the biomedical and technology sectors in general such as operational risks in development, research and regulatory delays or changes in plans with respect to research projects or capital expenditures; the uncertainty of the market; the uncertainty of estimates and projections relating to costs and expenses; health, safety and environmental risks; marketing and commercialization; loss of markets; competition; ability to access sufficient capital; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws, and government regulations, and other risks identified in the recent information circular available on www.sedar.com. Accordingly, readers should not place undue reliance on the forward-looking statements, timelines and information contained in this news release.

No undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.